A new study recently published by researchers in the Journal of Urology, says a new prostate screening exam has been successfully developed as well as tested. The new prostate test combines novel drug therapy with PSA level changes over a time period to identify males with a higher PSA who are at higher risks of developing an aggressive cancer though their biopsies were negative.
The most recent study shows that PSA might be a much more effective way for determining prostate cancer when it is used in addition to a therapy of drugs compared to the present stand-along test.
Dr. Steven Kaplan, a leading researcher and the director at the New York Presbyterian Medical School’s Iris Cantor Health Center, said that the value of PSA is being debated more and more, our study shows when it is used in a specific way, it is of great value in pinpointing men with prostate cancer that was previously undetected.
Kaplan calls his patient group, a “diagnostic dilemma” for many physicians despite evidence that biopsies are more and more effective in detecting prostate cancer. Many patients that have the cancer are continuing to show negative in their biopsies. Kaplan insists that just the PSA test by itself is not the best indicator of the detecting prostate cancer.
The study team enrolled 276 men who had a PSA rating of more than 4 and had a digital rectal examination that was normal and a minimum of two biopsies that were negative.
